PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Vardenafil - Erectile dysfunction combination therapy
PAD Profile : Vardenafil - Erectile dysfunction combination therapy
Keywords :
Phosphodiesterase type 5 inhibitors, ED, Impotence
Brand Names Include :
Levitra
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
Other Indications
Additional Documents
Type
Document
Review Date
Policy Statement
Erectile dysfunction oral and non oral combination treatments - Policy statement PCN 24-2012 - Jun 2
01 June 2025
Committee Recommendations
Date
Committee Name
Narrative
27 June 2012
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Use of both oral and non-oral combination treatments for erectile dysfunction in patients who had not responded or had a sub-optimal response to monotherapy was considered.The network members concurred that based on the limited available evidence, noting the feedback from clinicians, that combination treatments should not be supported and a BLACK status should be given on the PAD.Please see policy statement from June 2012
Associated BNF Codes
07. Obstetrics, Gynaecology and Urinary-Tract Disorders
07.04.05. Drugs for erectile dysfunction